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Abstract 
Since the first so-called “medical marijuana” legislation was passed in California in 1996, a total 
of twenty states and the District of Columbia have passed laws permitting limited use of 
cannabis. Despite the changes in state laws, cannabis remains illegal for any purpose under 
federal law. Changes in state laws have coincided with a renewed interest in the substance for the 
treatment of a variety of conditions. There has been a significant increase in published data over 
the past twenty years examining the efficacy of cannabis as an appetite stimulant, antiemetic 
agent, and analgesic adjuvant. The purpose of this meta-analysis was to synthesize published 
data on cannabis use as an analgesic agent. Five studies meeting inclusion criteria were located 
through searches of online databases, review of reference lists, author correspondence, and 
review of clinical trials databases. Meta-analysis was conducted using fixed-effects modeling. 
The overall effect of mean reduction of pain intensity was -4.895 (Z-score) with an associated p 
value of 0.003. The combined standardized mean difference (SMD) was -0.362 (CI -0.507 to -
0.217), indicating on average a moderate significant reduction in pain intensity for patients with 
chronic pain. As the legal status of the substance evolves, additional research is needed to 
establish evidence-based clinical recommendations regarding the use of medicinal cannabis in 
pain management. 
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Chapter One: Introduction 
Background 
In the past decade, there has been a renewed interest in the use of cannabis for therapeutic 
purposes to treat a variety of ailments and conditions. Despite federal prohibition of the 
substance, so called “medical marijuana” laws have been enacted in the United States in twenty 
states and the District of Columbia over the last 16 years (Procon, 2013). The literature is replete 
with studies regarding clinically available synthetic cannabinoid agents. Given the legal 
ramifications, however, data regarding the clinical use of herbal cannabis is much more limited. 
The purpose of this project is to review the available literature and, using meta-analytic 
methodology, evaluate what is currently known regarding the effects of cannabis in the treatment 
of chronic pain. 
Policy Influences 
 At the present time, the Drug Enforcement Administration (DEA) classifies cannabis as a 
“Schedule I” substance. According to the Comprehensive Drug Abuse Prevention and Control 
Act of 1970, categorization as a Schedule I substance means that the substance has been deemed 
to have no accepted medical use, a high potential for abuse, and a lack of any accepted margin of 
safety for usage. The placement of cannabis within this schedule remains controversial. All three 
of these requirements have been challenged through several formal petitions to the DEA over the 
past three decades (Gettman, 2004; Americans for Safe Access v. DEA, 2012). A total of twenty 
states and the District of Columbia have enacted legislation allowing for medical use of cannabis 
under a variety of conditions (Table 1). While this new legislation permits usage under state 
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laws, cannabis remains illegal for any purpose under federal law, except under very limited 
conditions for research purposes (Table 1).  
 Since the first medical marijuana legislation was enacted in California in 1996, there has 
been a significant increase in published data regarding the medical use of cannabis in the 
treatment of a variety of conditions. There is a considerable amount of published literature 
related to the ability of medicinal cannabis to promote appetite and minimize weight loss in 
chronic and terminal disease states such as AIDS and cancer (Machado Rocha, Stéfano, De 
Cassia Haiek, Rosa Oliveira, & Da Silveira, 2008; Tramér et al., 2001). The FDA-approved 
cannabinoid agonist dronabinol (Marinol) is labeled for use to promote appetite in chronic 
disease states and treat nausea and vomiting associated with chemotherapy (“New Drug 
Approvals,” 1985).  
 While evidence of the analgesic properties of cannabis was published in the 19
th
 century 
(O’Shaughnessy, 1843), the use of cannabis for this purpose diminished significantly into the 
early 20
th
 century. The recognition of the analgesic potential of cannabis in Europe and the 
United States emerged around the same time as the invention of the hypodermic needle in 1857. 
During the middle and late 19
th
 century, a variety of cannabis preparations were marketed in 
Europe and the United States for the treatment of discomfort related to numerous common 
ailments. At the turn of the 20
th
 century, cannabis continued to be recommended by mainstream 
physicians and maintained a place on pharmacopeias in both the United States and Britain 
(Russo, 1998). Dr. William Osler, one of the founders of Johns Hopkins Hospital recommended 
cannabis for the treatment of migraine headaches as late as 1915 (Osler & McCrae, 1915). 
However, a number of factors contributed to a decreased prevalence of these preparations going 
further into the 20
th
 century, including an association of the use of cannabis with certain classes 
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of people, vaccines for diseases that cannabis previously served to treat symptoms of, effective 
treatments for a number of diseases, the discovery of aspirin, increased opioid usage, and a 
preference for parenteral administration of medications (Grinspoon & Bakalar, 1993).  
 More recent research that has emerged in the last two decades has confirmed historical 
data and anecdotal evidence that cannabis is useful as an appetite stimulant, antiemetic agent, 
and analgesic adjuvant. In 1999, the United States Institute of Medicine (IOM) published an 
extensive report on the topic of medical marijuana, concluding that cannabinoids most likely 
play a role in pain modulation. Further, the 1999 IOM report suggested that cannabis has an 
acceptable margin of safety and recommended further research on the medicinal use of cannabis 
for a variety of conditions, including chronic pain states.  
Abbreviated Literature Review 
Mechanism of Action 
It has long been recognized that cannabis possesses analgesic properties (O’Shaughnessy, 
1843; Dixon, 1899). Recent studies have suggested that cannabis promotes analgesia through 
supraspinal modulation of nociception via the periaqueductal grey (PAG)-rostral ventromedial 
medulla (RVM)-dorsal horn (DH) axis (Palazzo, Luongo, Novellis, Rossi, & Maione, 2010). In 
addition to the role in central modulation of pain, there is also data to support a peripheral action 
of cannabis via peripheral cannabinoid type 1 (CB1) receptors (Richardson, Kilo, & Hargreaves, 
1998).  
Conflicting Findings With Hyperalgesia 
The antinociceptive and antihyperalgesic properties of cannabis present in a delayed 
biphasic manner with a window of analgesia at lower doses and increased nociception at high 
doses (Wallace et al., 2007). The biphasic nature of the analgesic dose-response complicates 
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assessment of the analgesic properties of cannabis. A study by Kraft et al. (2008) actually 
demonstrated the development of a hyperalgesic state as a result of oral cannabis extract. 
Participants in the Kraft et al. study received controlled localized ultraviolet burns to their lower 
extremities to provide a model for evaluating heightened sensitivity to pain. Kraft et al. found 
that participants who received higher doses of oral cannabis extracts demonstrated heightened 
sensitivity to pain, or hyperalgesia, over a larger area. Comparison of the Kraft et al. findings 
with the findings by Wallace et al. is problematic for several reasons. Participants in the Kraft et 
al. study received capsules of cannabis extract rather than inhaled herbal cannabis, allowing for 
the possibility that first-pass metabolism and pharmacokinetic variability may have contributed 
to the different findings. When tetrahydrocannabinol (THC) is administered orally, only 10-20% 
of the compound reaches the systemic circulation unchanged (Agurell et al., 1986). An additional 
issue is that plasma levels of active compounds were not monitored in the Kraft et al. (2008) 
study, making direct comparison with the dosing in the Wallace et al. (2007) study problematic. 
Finally, cannabis extracts commonly contain one or two active compounds, such as 
tetrahydrocannabinol or cannabidiol. Herbal cannabis smoke is known to contain more than 525 
components, at least 80 of which have been shown to be biologically active (Radwan et al., 
2009; ElSohly & Slade, 2005). Generalizability of findings utilizing oral cannabis preparations 
that contain one or two active compounds with inhaled herbal cannabis is limited.  
Experimental Trials Using Cannabis 
Human research on the clinical benefits of cannabis has been limited by legal restrictions, 
but available data indicates a potentially beneficial effect of cannabis for a variety of pain states. 
Treatment of neuropathic pain in multiple sclerosis has been improved by the use of cannabis in 
clinical trials (Hosking & Zajicek, 2008). In a randomized controlled trial by Ware et al. (2010), 
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patients suffering from chronic neuropathic pain who smoked cannabis cigarettes experienced 
reduced pain intensity and improved sleep without significant side effects. The analgesic effects 
observed in the study by Ware et al. were absent in the control group, who received cannabis 
with a reduced quantity of active compounds. Research published previously indicated similar 
analgesic benefits to patients suffering from neuropathic pain. A randomized controlled trial 
conducted by Ellis et al. (2009) found that patients who received cannabis containing 8% THC 
experienced a significant reduction in HIV-associated neuropathic pain when compared with the 
placebo group (who received cannabis with THC removed). The 2009 Ellis et al. study replicated 
findings from an earlier study by Abrams et al. (2007a) that found a similar reduction in HIV-
associated neuropathic pain in participants who received cannabis with THC present when 
compared with participants who received cannabis with THC removed. 
 Recent research has also demonstrated opioid-sparing properties of cannabis when it is 
used as an adjunct agent in pain management. Cannabis contributes to cumulative analgesia, 
reduces opioid consumption, and prevents or diminishes development of tolerance to and 
withdrawal from opioids (Lucas, 2012). An inpatient open trial conducted by Abrams, Couey, 
Shade, Kelly and Benowitz (2011) demonstrated that vaporized cannabis reduced pain by an 
average of 27% in chronic pain patients receiving twice-daily dosing of sustained-release 
morphine or oxycodone without altering plasma levels of opioids. Research findings of improved 
analgesia and reduced opioid consumption strongly suggest a beneficial role for cannabis as a 
potential adjunct agent in some patients experiencing chronic pain. A study by Wilsey et al. 
(2008) further supported the role of active cannabinoids in the analgesic benefits of cannabis 
with findings that both “high-dose” (7% THC) and “low-dose” (3.5% THC) produced significant 
reductions in neuropathic pain when compared with placebo. 
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Problem 
Meta-analysis has been conducted on the much larger body of research investigating 
commercially produced THC pharmaceutical agents. A 2009 systematic review and meta-
analysis conducted by Martín-Sánchez, Furukawa, Taylor, and Martin demonstrated a moderate 
analgesic effect of cannabinoid preparations that may be partially or completely offset by 
negative side effects. The review by Martín-Sánchez et al. evaluated eighteen clinical trials from 
1975-2008. All of the studies included in the Martín-Sánchez et al. meta-analysis utilized THC 
preparations as the treatment intervention rather than herbal cannabis. Prior literature reviews 
such as the 2002 review by Bagshaw and the 2001 review by Campbell et al. described similar 
findings of modest analgesic effects mitigated by significant side effects. Both of these older 
reviews also suffer the same limitation of focusing solely on THC preparations rather than herbal 
cannabis preparations that contain a variety of active compounds. To date, no meta-analysis has 
been published regarding clinical trials of herbal cannabis. 
 As discussed in the abbreviated review of literature, several randomized controlled trials 
have been published recently that evaluated the effect of herbal cannabis as an analgesic adjunct 
agent in the treatment of neuropathic pain. Several of the cited studies were conducted at the 
University of California Center for Medicinal Cannabis Research (CMCR) with support from the 
Department of Health and Human Services (HHS), the National Institute on Drug Abuse 
(NIDA), and the Food and Drug Administration (Grant, Atkinson, Gouaux, & Wilsey, 2012). 
This series of studies is frequently cited in editorials related to the topic of medicinal marijuana. 
However, each of the published studies evaluating herbal cannabis as an adjunct analgesic agent 
has relatively small numbers of participants (n = 15-50). Compiling quantitative findings from 
these studies may demonstrate a greater effect size and provide better-powered data on the topic.    
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Project Purpose 
The question to be addressed in this meta-analysis is whether the use of herbal cannabis 
by patients suffering from chronic pain provides a reduction in pain without an unfavorable side 
effect profile, as compared with currently available, FDA-approved medications and treatments. 
Inclusion criteria for studies to be reviewed and analyzed are randomized controlled trials of 
herbal cannabis in the treatment of chronic pain, limited to the English language. No date 
limitations were set for included studies, and any non-randomized trials were excluded. The 
participant population of included studies consisted of patients suffering from chronic pain, 
including pain resulting from comorbidities such as cancer, AIDS, and multiple sclerosis. Study 
interventions under evaluation included the usage of herbal cannabis, inhaled either through 
smoking or vaporization. Herbal cannabis will be compared against conventional therapies as 
well as against herbal cannabis that has been altered for reduced quantities of active compounds. 
Outcomes under evaluation include quantitative pain assessment utilizing visual analogue scales 
and 11-point numeric pain ratings.  
Definition of Terms 
Active Compound  
The term active compound refers to all pharmacologically active substances found in 
cannabis, including all cannabinoids. 
Cannabis  
The term cannabis is used interchangeably with the term marijuana, and both terms refer 
to the plants Cannabis Sativa and Cannabis Indica. 
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Cannabinoid  
The term cannabinoid refers to chemical compounds that interact with endogenous 
cannabinoid receptors, including tetrahydrocannabinol (THC). 
Chronic Pain  
Chronic pain is pain that is experienced, regardless of cause, for a duration of greater than 
three months. 
Herbal Cannabis 
 The term refers to the dried flowers and top leaves from the plants Cannabis Sativa and 
Cannabis Indica. 
Marijuana  
The term marijuana is used interchangeably with the term cannabis, and both terms refer 
to the plants Cannabis Sativa and Cannabis Indica. 
Neuropathic Pain  
Neuropathic pain refers to pain resulting from damage to nerves. Common examples of 
neuropathic pain include diabetic neuropathy, postherpetic neuralgia, HIV-associated 
neuropathy, alcoholic neuropathy, diabetic neuropathy, and chemotherapy-related neuropathy. 
Synthetic Cannabinoid 
 Any artificially synthesized compound or extract that interacts with endogenous 
cannabinoid receptor. 
 
 
 
 
 9 
Chapter Two: Review of Literature 
This chapter will review literature relevant to use of herbal cannabis in pain management. 
A literature search of Medline utilizing the keywords “cannabis” and “pain” in addition to the 
title phrases “systematic review” or “comprehensive review” returned nine results, of which four 
articles were relevant. An additional article was retrieved after a manual search of the list of 
publications from the Center for Medicinal Cannabis Research (CMCR) website. Additional 
searches utilizing the University of North Florida library “Onesearch” tool, as well as searches 
utilizing Pubmed and CINAHL did not return any additional unique relevant results. Five 
systematic reviews published between 2001 and 2012 were retrieved that were relevant to 
cannabis and pain management.  
Systematic Reviews of Cannabinoids 
The earliest systematic review relevant to the topic of cannabis and pain management 
was published in BMJ in 2001. By necessity, the 2001 review by Campbell et al. focused solely 
on oral cannabinoids, as no randomized controlled trials (RCTs) evaluating the effects of inhaled 
herbal cannabis as an analgesic had been published prior to this review. Campbell et al. 
performed a qualitative systematic review that included nine trials of oral cannabinoids with a 
total of 222 patients. The findings of this first review were that oral cannabinoids were only as 
effective as a single 60-milligram dose of codeine and were not beneficial in treating spasticity 
or neuropathic pain (Campbell et al.). In addition to poor analgesic efficacy, oral cannabinoids 
were found to often have undesirable psychotropic effects that worsened with increased dosages 
while not improving analgesic efficacy (Campbell et al.). 
Bagshaw published a comprehensive literature review regarding the therapeutic effects of 
cannabinoids and herbal cannabis the following year in 2002 in the Journal of Palliative Care. 
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The Bagshaw review was very broad in scope and evaluated the effects of cannabinoids and 
herbal cannabis in the treatment of nausea and vomiting, anorexia-cachexia syndrome, spasticity, 
seizures and epilepsy, hiccups, and migraines in addition to their use as an analgesic. Similar to 
the prior review by Campbell et al., the Bagshaw review referenced studies that only used oral 
cannabinoids when evaluating analgesic efficacy. Bagshaw described similar findings that oral 
cannabinoids provided modest analgesia similar to weak opioids, with dosing limited by adverse 
effects such as somnolence, dizziness, blurred vision, and dysphoria. 
In 2009, Martín-Sánchez et al. published a meta-analysis of cannabinoids in the treatment 
of chronic pain in the Journal Pain Medicine. Their review evaluated 18 RCTs that included a 
total of 809 participants. The work by Martín-Sánchez et al. is the first and, to date, only 
published meta-analysis of cannabinoid therapy for pain management. While the study makes 
reference to “cannabis treatment,” all of the trials included utilized oral cannabinoids (Martín-
Sánchez et al.). This study found cannabinoids reduced visual analogue scales (VAS) of pain by 
-0.61 (-0.84 to -0.37) but were offset by adverse effects such as altered perception, impaired 
motor function, and altered cognitive function (Martín-Sánchez et al.). Martín-Sánchez et al. 
concluded from their analysis that cannabinoids entailed more risk than benefits in the treatment 
of chronic pain. 
Systematic Reviews of Herbal Cannabis 
A systematic review published in 2011 in the British Journal of Clinical Pharmacology 
was the first to include analysis of RCTs of inhaled herbal cannabis (Lynch & Campbell). The 
review by Lynch and Campbell referenced “cannabinoids” in their study title, but their combined 
analysis looked at studies of both oral cannabinoids and inhaled herbal cannabis. They reviewed 
a total of 18 RCTs, with four of the trials evaluating inhaled herbal cannabis (Abrams et al., 
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2007a; Ellis et al., 2009; Ware et al., 2010; Wilsey et al., 2008). All four of the inhaled herbal 
cannabis trials referenced by Lynch and Campbell are included in this meta-analysis. In their 
combined systematic review of both oral synthetic cannabinoids and inhaled herbal cannabis, 
Lynch and Campbell concluded that cannabinoids and herbal cannabis are safe and demonstrate 
modest effectiveness in the treatment of neuropathic pain as well as fibromyalgia and rheumatoid 
arthritis. A particularly significant finding from the Lynch and Campbell review was that all four 
of the trials that evaluated herbal cannabis found positive treatment effects without any serious 
adverse effects reported. Two of the four herbal cannabis trials evaluated by Lynch and 
Campbell found beneficial effects in the treatment of HIV neuropathy, a type of neuropathic pain 
that is often not responsive to traditional therapy (Phillips, Cherry, Cox, Marshall, & Rice, 2010). 
An article published in 2012 by Grant et al. provided a comprehensive review of both 
oral cannabinoids and inhaled herbal cannabis. The review by Grant et al. included evaluation of 
several of the first of a series of studies on inhaled herbal cannabis that were conducted with 
funding provided by the CMCR. The Medical Marijuana Research Act of 1999 established the 
CMCR and provided a total of 8.7 million dollars of funding for research that was conducted 
from 2000-2012 (Hecht, 2012; Grant, 2012). The published studies on inhaled herbal cannabis 
for pain management conducted with funding from the CMCR, as reviewed by Grant et al. 
(2012), demonstrated a consistent reduction in pain intensity of 34-40 percent compared to 17-20 
percent with placebo (herbal cannabis with active compounds removed). These findings are 
clinically relevant, as a reduction of chronic pain intensity by greater than 30 percent is 
associated with improved quality of life (Farrar, Young, LaMoreaux, Werth, & Poole, 2001; 
Grant et al., 2012).  
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Review of CMCR-Funded Research 
The CMCR has provided funding for much of the research relevant to herbal cannabis 
that has been published since the turn of the century. Established by a California ballot initiative 
in 1999, the CMCR has stated research goals that transition through three stages: research on 
smoked cannabis, research on alternative cannabis preparations or delivery systems (such as 
vaporization), and research regarding molecules targeting the endocannabinoid system (CMCR, 
2010). Clinical trials that have been conducted examining the efficacy of herbal cannabis as an 
analgesic agent will be discussed in subsequent chapters. A CMCR-funded RCT that 
investigated the pharmacodynamics of herbal cannabis through a model of neuropathic pain with 
healthy volunteers was discussed earlier (Wallace et al., 2007). The study by Wallace et al. found 
(similar to many pharmaceutical agents) that herbal cannabis likely has a therapeutic window of 
dosing. Subtherapeutic dosing of herbal cannabis provides no analgesia, while supratherapeutic 
dosing appears to potentially contribute to an increase in pain, or hyperalgesia (Wallace et al.). 
An earlier study conducted under similar laboratory conditions that evaluated a model of 
analgesia also found a dose-dependent antinociceptive effect (reduced sensation of pain) from 
herbal cannabis (Greenwald & Stitzer, 2000). The study by Greenwald and Stitzer also found 
that the analgesic effects of cannabis are not affected by opioid antagonists and likely are not 
derived from action at opioid receptors. Another CMCR-funded study discussed earlier was the 
open trial conducted by Abrams et al. (2011) with chronic pain patients in an inpatient setting. 
Abrams et al. (2011) found that vaporized cannabis inhaled three times daily augmented the 
effects of opioid therapy without altering plasma opioid levels. Patients in the Abrams et al. 
(2011) open trial experienced an average pain reduction of 27% (95% confidence interval 9, 46), 
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a clinically relevant reduction in pain that is consistent with the findings in CMCR-funded RCTs 
described by Grant et al. (2012). 
Summary 
 Much of the highest-level evidence (systematic reviews) relevant to cannabis focuses 
solely on oral cannabinoid agents. High quality RCTs evaluating the role of herbal cannabis as 
an analgesic agent are largely limited to those conducted by the CMCR over the past few years, 
with systematic reviews prior to the past few years omitting these results. Results of the reviews 
by Lynch & Campbell (2011) and Grant et al. (2012) of inhaled herbal cannabis describe 
clinically relevant reductions in chronic pain intensity that is less limited by adverse reactions 
than prior reviews that focused solely on oral cannabinoids. While public funding for research 
through the CMCR is currently exhausted (Hecht, 2012), there are still additional study results 
pending publication. Currently published results on inhaled herbal cannabis suggest a potential 
beneficial role in pain management. It is possible that patients may experience less adverse 
effects with herbal cannabis than with currently available oral cannabinoids. With continued 
research, the CMCR may be able to continue into the latter stage of their stated research 
objectives and identify molecular targets in the endocannabinoid system that may balance 
clinical efficacy with minimal adverse effects. 
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Table 1 
States That Have Enacted Medical Marijuana Legislation 
State Year Passed How Legislation Passed 
California 1996 Ballot (56%) 
Alaska 1998 Ballot (58%) 
Oregon 1998 Ballot (55%) 
Washington 1998 Ballot (59%) 
Maine 1999 Ballot (61%) 
Colorado 2000 Ballot (54%) 
Hawaii 2000 Senate Bill (32-18 in House; 13-12 in Senate) 
Nevada 2000 Ballot (65%) 
Montana 2004 Ballot (62%) 
Vermont 2004 Senate Bill (22-7), House Bill (82-59) 
Rhode Island 2006 Senate Bill (52-10 in House; 33-10 in Senate) 
New Mexico 2007 Senate Bill (36-31 in House; 32-3 in Senate) 
Michigan 2008 Ballot (63%) 
Arizona 2010 Ballot (50.1%) 
District of Columbia 2010 Amendment (13-0 vote) 
New Jersey 2010 Senate Bill (48-14 in House; 25-13 in Senate) 
Delaware 2011 Senate Bill (27-14 in House; 17-4 in Senate) 
Connecticut 2012 House Bill (96-51 in House; 21-13 in Senate) 
Massachusetts 
Illinois 
New Hampshire 
2012 
2013 
2013 
Ballot (63%) 
House Bill (61-57 in House; 35-21 in Senate) 
House Bill (284-66 in House; 18-6 in Senate) 
 
Note. Adapted from “Summary Chart: 20 states and DC that have enacted laws to legalize medical marijuana” by procon.org 
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Chapter Three: Methods 
This chapter will discuss methods utilized in evaluating and consolidating published data 
on herbal cannabis in pain management. Meta-analysis will be conducted on quantitative 
findings from published studies. The objective will be to provide organized results regarding the 
efficacy of herbal cannabis in pain management that are better powered than those found in 
individual studies. 
Search Strategy 
A literature search of Medline utilizing the keywords “cannabis” or “marijuana” and 
“pain” in addition to the title phrases “cannabis” or “marijuana” or “cannabinoid” or 
“cannabinoid-opioid” and “pain” or “painful” or “neuropathy” or “antinociceptive” or 
“nociceptive” or “analgesic” or “analgesia” or “hyperalgesia” and “trial” or “volunteers” or 
“humans” or “interaction” returned nineteen results. Inclusion criteria for study evaluation are 
RCTs of inhaled herbal cannabis in the treatment of chronic pain, limited to the English language 
studies. No date limitations were set for included studies. Exclusion criteria included any non-
randomized clinical trials. Of the nineteen results, seven of the studies evaluated inhaled herbal 
cannabis. Two of the studies evaluated a model of pain in a laboratory setting and were discussed 
previously (Greenwald & Stitzer, 2000; Wallace et al., 2007). One study was an open (non-
randomized) trial of opioid interaction with inhaled herbal cannabis (Abrams et al., 2011). Four 
of the results met the inclusion criteria of RCTs evaluating inhaled herbal cannabis in chronic 
pain patients. An additional article (Corey-Bloom et al., 2012) was retrieved after a manual 
search of the list of publications from the CMCR website. After email correspondence with the 
primary authors of all retrieved studies, an abstract for an additional article that was in press at 
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the time of the initial search was located (Wilsey et al., 2013), bringing the total of studies 
meeting inclusion criteria to six (see Appendix). Additional searches utilizing the University of 
North Florida library “Onesearch” tool, as well as searches utilizing Pubmed and CINAHL did 
not return any additional unique relevant results.  
Further review of all study references also did not yield any additional unique relevant 
results. A search of the NIH database of registered clinical trials at ClinicalTrials.gov with the 
keyword “cannabis” yielded 264 studies, with no additional unique relevant results for 
completed studies, either published or unpublished. The last search was completed February 15, 
2013. No unpublished studies were located through any source.   
Study Selection  
 Five out of the six studies recruited patients with chronic neuropathic pain (Abrams et al., 
2007a; Ellis et al., 2009; Ware et al., 2010, Wilsey et al., 2008; Wilsey et al., 2013). Two of 
these studies were specific to patients with Human Immunodeficiency Virus (HIV) neuropathy 
(Abrams et al., 2007a; Ellis et al., 2009). One study evaluated participants with multiple sclerosis 
(Corey-Bloom et al., 2012). All of the studies were limited to adult participants. The study by 
Abrams et al. (2007a) further limited participants to individuals with self-reported prior 
experience with smoked marijuana. 
 All six studies evaluated were double-blinded, randomized placebo-controlled trials. 
Sample sizes ranged from 23 to 50 subjects. One study utilizes a parallel design (Abrams et al., 
2007a), with the other five studies utilizing crossover study designs (Corey-Bloom et al., 2012; 
Ellis et al., 2009; Ware et al., 2010, Wilsey et al., 2008; Wilsey et al., 2013). Treatment groups in 
all studies received inhaled herbal cannabis with concentrations of THC ranging from 1.29 to 7 
percent. Placebos utilized in the studies were herbal cannabis provided by NIDA with active 
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compounds removed. Five out of the six studies utilized smoked herbal cannabis for drug 
delivery (Abrams et al., 2007a; Corey-Bloom et al., 2012; Ellis et al., 2009; Ware et al., 2010; 
Wilsey et al., 2008). One of the six studies utilized vaporized cannabis for drug delivery (Wilsey 
et al., 2013). With the exception of the 2010 study by Ware et al., which was conducted in the 
province of Quebec in Canada, all studies were conducted in the state of California in the United 
States. 
Outcome Measures 
 All six studies evaluated pain intensity as an outcome. Five of the studies evaluated pain 
intensity as a primary outcome measure (Abrams et al., 2007a; Ellis et al., 2009; Ware et al., 
2010; Wilsey et al., 2008; Wilsey et al., 2013). One study evaluated muscle spasticity as a 
primary outcome and pain intensity as a secondary outcome (Corey-Bloom et al., 2012). Four of 
the studies utilized a 100-millimeter visual analogue scale (VAS) as an instrument to measure 
pain intensity (Abrams et al., 2007a; Corey-Bloom et al., 2012; Wilsey et al., 2008; Wilsey et al., 
2013). One study utilized an 11-point numeric rating scale (NRS-11) as an instrument to measure 
pain intensity (Ware et al., 2010). One study utilized a 20-point verbal rating scale (VRS-20) as 
well as a VAS as instruments to measure pain intensity (Ellis et al., 2009). All three of the 
instruments utilized to assess pain in the studies have been found to be reliable and valid in the 
measurement of pain intensity (Hjermstad et al., 2011). The frequency with which pain intensity 
was evaluated varied from study to study. Three of the studies evaluated pain intensity on a daily 
basis during the study period (Abrams et al., 2007a; Corey-Bloom et al., 2012; Ware et al., 
2010). One study evaluated pain intensity on a weekly basis during the study period (Ellis et al., 
2009). Two studies (Wilsey et al., 2008; Wilsey et al., 2013) evaluated pain intensity on an 
hourly basis for the six hours of each study arm.   
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Statistical Analysis 
All included studies reported differences between baseline and final pain intensity ratings 
for each of the intervention groups. Difference (Cannabis - Placebo) in means of the pain ratings 
are reported and tested for significance. Differences in means (Cannabis - Placebo) were 
compiled, along with their standard errors, sample sizes, and p values. Meta-analysis was 
performed to quantify the effect of treatment (Cannabis) as the standardized mean difference 
(SMD) between treatment and control (Placebo) groups in each study as well to achieve an 
overall estimate of global effect size based on all studies. Weighting was carried out by reference 
to the degree of study precision using the method of the inverse of the variance. The 2013 study 
by Wilsey et al. did not report group means or standard errors of means or differences in means 
for pain intensity measures. It also used a different method of analysis (Factorial ANOVA) 
compared with the other studies. It was not possible to include this study in the meta-analysis 
and it was excluded from evaluation. The earlier 2008 study by Wilsey et al. included two 
treatment groups in a crossover design, and these were included as separate entries in the meta-
analysis. 
 Heterogeneity between studies was statistically determined using the Q
2
 test and I
2
 
statistic measures. The results of the Q
2
 and I
2
 were insignificant, providing evidence of 
homogeneity among the studies evaluated.
 
It is possible to conduct meta-analysis with either 
random-effects or fixed effect modeling. Fixed-effect modeling assumes that there is one true 
effect size amongst all studies evaluated and that differences in effects are a result of sampling 
error (Borenstein, Hedges, Higgins, & Rothstein, 2010). Random-effects modeling allows for the 
possibility of different true effect sizes and is appropriate for meta-analysis of studies with 
significant variation in populations studied or interventions utilized (Borenstein et al.). After 
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ascertaining evidence of homogeneity amongst studies, it was determined that fixed-effect 
modeling was appropriate for this meta-analysis. However, meta-analysis was performed with 
both fixed-effect and random effects modeling, and both models produced the same results. 
Possible publication bias was ascertained by means of funnel plots. Specialized meta-analysis 
software, Comprehensive Meta Analysis version 2.2.064, was used to perform the complete 
analyses.  
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Chapter Four: Results 
 This chapter will present the quantitative meta-analysis data from five of the six studies 
that met the criteria for evaluation. One of the studies (Wilsey et al., 2013) was not included in 
the meta-analysis as a result of insufficient reported results that precluded inclusion in the meta-
analysis. 
Meta-Analysis Results 
Results obtained from meta-analysis of efficacy herbal cannabis in reducing chronic pain 
intensity are reported in Table 2. The results show that all studies yielded standardized results in 
the same direction. The test statistic value of heterogeneity is obtained as 0.990 with a p-value of 
0.963 implying between studies heterogeneity was almost certainly absent. This confirms that the 
variability between study estimates is too small to assume that they are estimating a different 
underlying treatment. The I
2
 statistic is 0%, which implies that real heterogeneity is 0% to the 
total variance across the observed effect estimate.  
 The test value of overall effect of mean reduction of pain intensity is -4.895 with an 
associated p value of 0.003. At the 1% level of significance, this test is statistically significant. 
Based on these results, it can be concluded that there is a significant difference between the 
Cannabis and Placebo groups in pain intensity reduction. The combined standardized mean 
difference (SMD) is -0.362 (Confidence Interval -0.507 to -0.217). The negative SMD value 
ensured a greater reduction of pain intensity by Cannabis treatment than the Placebo. The 95% 
confidence interval around this estimate is not reasonably wide, indicating no uncertainty in the 
pooled result. According to Cohen’s rules, a moderate impact of Cannabis on pain reduction can 
be concluded (Cohen, 1988). As a final finding, the funnel plot in Figure 1 shows no sign of 
asymmetry. Therefore, there is no evidence of possible publication bias.  
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Table 2 
 
Meta-Analysis of Herbal Cannabis in Reduction of Pain Intensity   
 
Statistics for each study 
Study name 
Std. diff. in 
means 
Standard 
error 
Variance 
Lower 
limit 
Upper 
limit 
Z-value p-value 
Standardized Mean Difference, Fixed Effects, 95%  C.I. 
Corey-Bloom et al., 2012 -0.467 0.192 0.037 -0.844 -0.090 -2.429 0.015 
Ware et al., 2010 -0.441 0.218 0.048 -0.869 -0.013 -2.019 0.043 
Ellis et al., 2009 -0.427 0.197 0.039 -0.814 -0.040 -2.165 0.030 
Wilsey et al., 2008 (3.5%) -0.345 0.182 0.033 -0.702   0.012 -1.897 0.058 
Wilsey et al., 2008 (7%) -0.320 0.181 0.033 -0.675  0.035 -1.765 0.077 
Abrams et al., 2007 -0.272 0.144 0.021 -0.555  0.010 -1.891 0.059 
Combined -0.362 0.074 0.005 -0.507 -0.217 -4.895 0.000 
Test for Heterogeneity: Q = 0.990, p-value = 0.963, I
2 = 0.00% 
Test for overall effect: Z = -4.895, p-value = 0.000 
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Figure 1: Funnel plot to assess publication bias. 
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Chapter Five: Discussion 
The following chapter will discuss the results from the meta-analysis. Implications for 
practice will be discussed, as well as the limitations of this study and implications for future 
research. 
Results of this meta-analysis demonstrate a statistically significant reduction in pain 
intensity in chronic pain patients receiving inhaled herbal cannabis. These findings are consistent 
with the findings discussed in a recent narrative review (Grant et al., 2012). The narrative review 
by Grant et al. included discussion of four (Abrams et al., 2007a; Ellis et al., 2009; Ware et al., 
2010; Wilsey et al., 2008) of the six studies that met inclusion criteria, with the two most recent 
studies (Corey et al., 2012; Wilsey et al., 2013) not included in the discussion. The findings in 
the combined synthetic cannabinoid and herbal cannabis review by Lynch and Campbell (2011) 
were similar to the herbal cannabis discussion in the Grant et al. review, with the combined 
review describing modest reductions in pain and the herbal cannabis review describing 
significant reductions in pain intensity, both consistent with the findings in this meta-analysis. 
Additionally, results of this meta-analysis are consistent with the sole RCT that was excluded 
from data analysis (Wilsey et al., 2013).
 
Compiled data from all available RCTs utilizing RCTs 
demonstrate moderate but statistically significant efficacy in reducing pain intensity in chronic 
pain patients. The data also lacked evidence of publication bias. 
Implications for Practice 
In states where regulations permit medical usage, herbal cannabis may represent an 
option for chronic pain patients as an analgesic adjuvant with opioid-sparing properties (Abrams 
et al., 2011). These findings present a number of implications for advanced nursing practice. 
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However, the direct relevance of these findings varies significantly between different practice 
settings. 
 Within the perioperative setting, the future therapeutic potential of the substance is 
essentially completely negated by practical limitations to administration as well as some 
potential concerns for pharmaceutical interactions and airway complications. For example, 
chronic cannabis usage has been shown to increase propofol dosage requirements for laryngeal 
mask airway placement (Flisberg et al., 2009). Although extremely rare, one case study 
documented an instance of acute uvulitis and partial airway obstruction that was thought to have 
resulted from recently smoked cannabis (Mallat, Roberson, & Brock-Utne, 1996). The authors of 
this single case study suggested that the higher combustion temperature of cannabis (relative to 
tobacco) paired with deeper and sustained inhalation might account for increased mucous 
membrane irritation in some cannabis smokers (Mallat et al.). Because of these concerns, 
recommendations in some anesthesia literature are that elective surgical procedures should be 
delayed for patients that have smoked herbal cannabis within 72 hours prior to surgery 
(Dickerson, 1980; Mallat et al., 1996). Other recommendations from anesthesia literature include 
simply treating patients with a history of smoking cannabis similarly to patients with a history of 
smoking tobacco due to potential similarities in airway hyperreactivity (Bryson & Frost, 2011).  
Existing research demonstrates efficacy of herbal cannabis as an analgesic agent. 
However, a significant amount of additional research is needed to achieve the complete goals of 
the CMCR of establishing efficacy with inhaled cannabis prior to researching other delivery 
methods and eventually researching molecules that target the endocannabinoid system (Grant, 
2012). It is possible that targeted delivery of cannabinoid agonists may eventually be feasible 
within the perioperative setting for acute pain management. However, current delivery methods 
 25 
create a potential for adverse airway reactions that, in addition to potential drug interactions, 
make herbal cannabis unsuitable for the perioperative period. 
Within the outpatient and primary care settings, patients may present who are using 
cannabis or (in jurisdictions where this is permitted) are seeking information and 
recommendations regarding the substance from practitioners. While further research is still 
needed to establish optimum dose and frequency, the findings of this meta-analysis support the 
recommendation of herbal cannabis as an adjunct analgesic agent for chronic pain patients. 
In the palliative care setting, herbal cannabis provides the additional benefits of 
antiemetic properties and appetite stimulation (Machado Rocha et al., 2008; Tramér et al., 2001). 
Since the substance remains prohibited under federal law, providers do not “prescribe” herbal 
cannabis per se, but rather “recommend” it to patients, subject to state regulations that vary 
considerably. With the rapid pace of regulatory changes in this area, providers working in 
jurisdictions where medical cannabis initiatives are proposed or have passed may encounter 
questions from patients regarding the efficacy of the substance. The findings of this meta-
analysis support the efficacy of herbal cannabis in reducing pain intensity in patients suffering 
from chronic pain. 
Study Limitations 
 This meta-analysis had several limitations related to the available literature on this topic. 
There are a very limited number of RCTs from which to consolidate data. The RCTs that are 
available have small numbers of participants and vary somewhat in specific patient population 
and dosing regimen. As shown in the appendix, the RCTs included in this meta-analysis utilized 
herbal cannabis with concentrations of active compounds that varied somewhat from study to 
study. Additionally, the frequency of dosing and delivery method was not consistent across 
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studies. This meta-analysis was limited to English-language publications and did not evaluate 
any unpublished studies. 
 Some of these limitations are inherent to the technique of meta-analysis itself. A unique 
issue with studies utilizing herbal cannabis is the regulatory difficulty conducting such studies. 
Studies utilize herbal cannabis supplied by NIDA with uniform concentrations of active 
compounds (Grant, 2012). Research utilizing herbal cannabis has additional bureaucratic 
difficulties that may limit studies from being repeated to better confirm findings. Rather, what 
are available within the limited research that has been conducted are studies that evaluate the 
efficacy of herbal cannabis in slightly different and unique ways with slightly different 
participant populations.   
Implications for Future Research 
 Trials utilizing herbal cannabis are very limited and involve considerable regulatory 
restrictions to conduct. There is a great deal that is not well understood regarding the therapeutic 
value of the substance. In regards to the efficacy of herbal cannabis in treating chronic pain, there 
is a need for clinical trials to determine optimum dosage, timing, and delivery methods. 
Additionally, larger studies that stratify specific chronic pain populations could be conducted to 
determine which patients might be most responsive to herbal cannabis therapy. 
The sole RCT of herbal cannabis for chronic pain that was excluded from meta-analysis 
(Wilsey et al., 2013) did demonstrate similar findings of moderate analgesia in patients with 
treatment-resistant neuropathic pain. One unique aspect to the 2013 study by Wilsey et al. is that 
it is the first RCT to utilize vaporization as a delivery method for the inhaled cannabis. A prior 
open trial by Abrams et al. in 2011 used vaporized herbal cannabis and also found reduced pain 
intensity as well as reduced opioid consumption in chronic pain patients. Vaporization is able to 
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deliver similar levels of active compounds with patients experiencing lower plasma carbon 
monoxide levels and a general patient preference for vaporization over smoking (Abrams et al., 
2007b). With the known pulmonary complications of smoked cannabis (Bryson & Frost, 2011), 
there is a need for further studies using the safer delivery method of vaporized cannabis to better 
establish analgesic efficacy of vaporized cannabis in chronic pain patients. Another possibility 
for future research might include a comparison of efficacy between different delivery methods 
such as smoked, vaporized, and ingested herbal cannabis. It is possible that first-pass metabolism 
may play a role in the lower efficacy seen with oral cannabinoids. However, research in this area 
relates primarily to oral ingestion of specific cannabinoid extracts rather than unaltered herbal 
cannabis. Further research might reveal the impact of other active compounds in herbal cannabis 
as well as the impact of first-pass metabolism that may possibly limit the efficacy of oral 
delivery of herbal cannabis for some uses. 
Conclusion 
 Medicinal use of herbal cannabis is a controversial subject, but one that is in need of 
more evidence through objective, quality research trials. In light of the evolving attitudes 
regarding marijuana, it is an opportune time to investigate this substance further. More than half 
of Americans are now in favor of marijuana legalization, a statistic that is in stark contrast to 
attitudes towards the substance in prior decades (Pew Research Center, 2013). In the current 
sociopolitical environment, research can be conducted without as much concern for research 
findings disrupting the status quo. 
 The findings of this meta-analysis are consistent with all prior research on the subject, 
further demonstrating a moderate reduction in pain intensity with minimal side effects in chronic 
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pain patients with the use of herbal cannabis. Additional research is needed to better establish 
optimum therapeutic dosing regimens and factors related to safety and adverse reactions. 
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Appendix:  Experimental Studies Investigating Herbal Cannabis and Chronic Pain  
 
Author 
(Date) 
Design Sample Outcome Intervention Results Limitations 
Wilsey et 
al. (2013, 
in press) 
RCT 
(cross-
over) 
39 participants VAS Vaporized 
cannabis (or 
placebo 
cannabis) 
Analgesic effects 
observed in both 
“high-dose” and 
“low-dose” 
groups. 30% 
reduction in pain 
intensity 
compared to 
placebo.  
Potential for 
unmasking of 
blinding in 
crossover design 
Corey-
Bloom et 
al. (2012) 
RCT 
(cross-
over) 
37 participants VAS Smoked 
cannabis (or 
placebo 
cannabis) daily 
x3 days, 11 day 
washout 
between 
treatment groups 
VAS decreased by 
5.28 points more 
than placebo 
(p=0.008) 
Some participants 
prior cannabis 
users (self-
selection bias, 
potential 
unblinding) 
Ware et 
al. 
(2010) 
RCT 
(cross-
over) 
23 participants VAS Random 
assignment to 
receive smoked 
cannabis three 
times a day at 
four potencies 
(0%, 2.5%, 6%, 
9.4% 
tetrahydrocanna
binol) over four 
14-day periods 
in a crossover 
trial.  
Single inhalation 
of 9.4% 
tetrahydrocannabi
nol herbal 
cannabis three 
times daily for 
five days reduced 
pain intensity and 
improved sleep. In 
0% vs. 9.4% 
groups, pain was 
5.4 vs. 6.1 (95% 
CI, 0.02-1.4). 
Small number of 
participants. 
Tetrahydrocannabi
nol concentration 
limited by legal 
availability. The 
use of smaller 
fixed dosing of 
herbal cannabis 
may have limited 
the effect size. 
Ellis et 
al. 
(2009) 
RCT 
(cross-
over) 
28 participants Descriptor 
Differential 
Scale 
(DDS) & 
VAS 
Random, 
double-blind 
assignment to 
smoke herbal 
cannabis with 
8% 
tetrahydrocanna
binol or 1% 
(placebo) herbal 
cannabis four 
times daily for 
five consecutive 
days in 
crossover trial 
with two-week 
washout period . 
Pain relief was 
greater in active 
cannabis group vs. 
placebo (-3.3 
points on DDS, 
effect size = 0.60; 
p= 0.016). 
Subjects 
achieving ≥30% 
pain reduction 
with active 
cannabis vs. 
placebo were 0.46 
(95% CI 0.28, 
0.65) and 0.18 
(0.03, 0.32). 
Potential placebo 
effects, as most 
subjects were able 
to differentiate 
between treatment 
and placebo 
groupings by the 
end of second 
crossover period. 
Wilsey et 
al. 
(2008) 
RCT 
(cross-
over) 
38 participants VAS Random 
assignment to 
either high-dose 
(7% 
tetrahydrocanna
Analgesic effects 
were observed in 
both “high-dose” 
and “low-dose” 
groups when 
Brief observational 
period (6 hour 
sessions), possible 
placebo effect. 
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binol), low-dose 
(3.5% 
tetrahydrocanna
binol), or 
placebo 
cannabis. 
Patients inhaled 
smoked herbal 
cannabis during 
3 separate 6 
hour sessions, 
receiving each 
treatment group 
once, in random 
order. 
compared with 
placebo (VAS 
difference per 
minute of -0.0035, 
95% CI [-0.0063, 
-0.0007]) 
Abrams 
et al. 
(2007a) 
RCT 50 participants VAS Random 
assignment to 
3.56% cannabis 
cigarettes or 
placebo 
(cannabinoids 
extracted) 
group, with 
cigarettes 
smoked three 
times a day for 
five days. 
Cannabis 
significantly 
reduced pain vs. 
placebo. 
Daily pain was 
reduced by 
median of 34% 
(IQR = -71, -16) 
vs. median of 
17% (IQR = -29, 
8) for placebo.  
Single 
tetrahydrocannabin
ol concentration 
may limit 
comparison of 
findings with other 
studies. 
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